Oncology Corporate Profile
Mirati Therapeutics is a publicly-traded biopharmaceutical company engaged in the development of novel therapeutics for the treatment of cancer. Our compounds result from internal chemistry efforts targeting the active sites of enzymes that are key drivers of tumor growth. Our clinical development programs are focused on treating selected tumor types that express high levels of these targets in order to most effectively address unmet patient needs. Our lead program in clinical development is MGCD265, a multi-targeted small molecule kinase inhibitor for treatment of oncology patients with solid tumors. We are also evaluating development opportunities in oncology for mocetinostat, a spectrum-selective HDAC inhibitor and MGCD516, a kinase inhibitor with a distinct target profile.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|mocetinostat||HDAC inhibitor||Bladder cancer||II|
|mocetinostat||HDAC inhibitor||Diffuse large B-cell Lymphoma (DLBCL)||II|
|mocetinostat||HDAC inhibitor||Myelodysplastic Syndrome (MDS)||II|
|MGCD265||multiple tyrosine kinase inhibitor||Head & Neck cancer||I|
|MGCD265||multiple tyrosine kinase inhibitor||Non Small Cell Lung Cancer (NSCLC)||I|
|MGCD516||multiple tyrosine kinase inhibitor||Various cancer types||I|
|mocetinostat (+ MEDI4736)||HDAC inhibitor||Various cancer types||I||Medimmune|
View additional information on product candidates here »
3/27/2017 08:00 pm
3/15/2017 05:00 pm
3/9/2017 11:04 pm
3/9/2017 11:04 pm
3/9/2017 09:02 pm
3/9/2017 09:00 pm
[PR Newswire] - SAN DIEGO, March 9, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) ("the Company," "we," "our," "us," or "Mirati") today reported financial ...
2/13/2017 09:00 pm
[PR Newswire] - SAN DIEGO, Feb. 13, 2017 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Charles M. Baum, M.D, Ph.D., President and CEO of Mirati, will provide a corporate overview during ...